P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE

P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE

Bibliographic Details
Main Authors:	IDRIZOVIC A., COLLADO GIMBERT A., VAN BEERS E., COLOMBATTI R., BARTOLUCCI P., DE MONTALEMBERT M., BOARO M., BENEITEZ D., ORTUÑO A., RUIZ A., ISOLA I., CELA E., VAN WIJK R., RAB M., MAÑU PEREIRA M.
Format:	Article
Language:	English
Published:	Wiley 2022-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000873024.82912.2d

Similar Items

P1478: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE
by: A. Idrizovic, et al.
Published: (2022-06-01)

Challenges and Opportunities of Precision Medicine in Sickle Cell Disease: Novel European Approach by GenoMed4All Consortium and ERN-EuroBloodNet
by: Anna Collado, et al.
Published: (2023-03-01)

P1500: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
by: S. van der Veen, et al.
Published: (2022-06-01)

S265: RADIOMICS AND ARTIFICIAL INTELLIGENCE FOR IDENTIFICATION AND MONITORING OF SILENT CEREBRAL INFARCTS IN SICKLE CELL DISEASE: FIRST ANALYSIS FROM THE GENOMED4ALL EUROPEAN PROJECT
by: M. P. Boaro, et al.
Published: (2022-06-01)

P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
by: VAN DER VEEN S., et al.
Published: (2022-08-01)

O-02: RADIOMICS AND ARTIFICIAL INTELLIGENCE FOR IDENTIFICATION AND MONITORING OF SILENT CEREBRAL INFARCTS IN SICKLE CELL DISEASE: FIRST ANALYSIS FROM THE GENOMED4ALL EUROPEAN PROJECT
by: BIONDI R., et al.
Published: (2022-08-01)

Editorial for Special Issue “Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies”
by: Raffaella Colombatti, et al.
Published: (2019-09-01)

S266: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE
by: M. Rab, et al.
Published: (2022-06-01)

PB2518: OPTIMIZING THE DETECTION OF 2,3- DIPHOSPHOGLYCERATE IN DRIED BLOOD SPOTS OF PATIENTS WITH SICKLE CELL DISEASE: UNTARGETED METABOLOMICS WITHIN THE GENOMED4ALL PROJECT
by: Sigrid van der Veen, et al.
Published: (2023-08-01)

PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE
by: RAB M., et al.
Published: (2022-08-01)

PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
by: RAB M., et al.
Published: (2022-08-01)

P1492: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
by: M. Rab, et al.
Published: (2022-06-01)

5610325 VARIABILITY OF OXYGENSCAN PARAMETERS ACCORDING TO THE TYPE OF THERAPY IN CHILDREN WITH SICKLE CELL DISEASE: PRELIMINARY DATA FROM A FEASIBILITY STUDY
by: G. Reggiani, et al.
Published: (2023-04-01)

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: VAN DIJK M., et al.
Published: (2022-08-01)

Newborn Screening for Sickle Cell Disease in Europe
by: Yvonne Daniel, et al.
Published: (2019-02-01)

PW03-032 – Periodic fevers in children
by: Harper, C, et al.
Published: (2013)

A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease
by: Myrthe J. vanDijk, et al.
Published: (2024-02-01)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M. J. van Dijk, et al.
Published: (2022-06-01)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
by: M.J. van Dijk, et al.
Published: (2023-04-01)

P032 Correlation of lymphocyte infiltration (TILs) in breast cancer with prognosis
by: Z. Sanaat, et al.
Published: (2023-03-01)

PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW
by: R. Colombatti, et al.
Published: (2022-06-01)

5613081 GAPS IN DATA ON GLOBAL PREVALENCE AND BIRTH PREVALENCE OF SICKLE CELL DISEASE AND SICKLE CELL TRAIT: CALL FOR ACTION TO SCALE UP AND HARMONIZE DATA COLLECTION
by: R. Colombatti, et al.
Published: (2023-04-01)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
by: I Osunkwo, et al.
Published: (2022-01-01)

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
by: ANDEMARIAM B., et al.
Published: (2022-08-01)

Sickle cell disease: embedding patient participation into an international conference can transform the role of lived experience
by: Mariangela Pellegrini, et al.
Published: (2023-11-01)

Derivation of iPS cell line (ICGi032-A) from a patient affected with fragile X syndrome
by: M.M. Gridina, et al.
Published: (2021-12-01)

P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HCP–PATIENT RELATIONSHIP: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
by: B. Andemariam, et al.
Published: (2022-06-01)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
by: Marissa Traets, et al.
Published: (2023-08-01)

Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease
by: Camille Boisson, et al.
Published: (2021-04-01)

A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease From Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling
by: Annelies J. van Vuren, et al.
Published: (2021-03-01)

032 Cognitive deficits are associated with anosmia but not anxio-depressive symptoms in COVID-19
by: Anthony Byrne, et al.
Published: (2021-08-01)

Bacillus pumilus SAFR-032 Genome Revisited: Sequence Update and Re-Annotation.
by: Victor G Stepanov, et al.
Published: (2016-01-01)

SNS-032 Prevents Tumor Cell-Induced Angiogenesis By Inhibiting Vascular Endothelial Growth Factor
by: M. Aktar Ali, et al.
Published: (2007-05-01)

Abstract 032: Ovine Models for Cerebral Venous Catheter Access: A Single Center Experience
by: José M Morales, et al.
Published: (2023-11-01)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
by: Myrthe van Dijk, et al.
Published: (2023-08-01)

Sickle cell disease: challenging the past, looking to the future
by: Elena Cela
Published: (2022-07-01)

MANAGEMENT OF CHILDREN WITH SICKLE CELL DISEASE IN EUROPE: CURRENT SITUATION AND FUTURE PERSPECTIVES
by: Raffaella Colombatti, et al.
Published: (2016-07-01)

P.032 CORRELATION OF AORTIC STIFFNESS WITH SEVERITY OF ERECTILE DYSFUNCTION
by: N. Ioakeimidis*, et al.
Published: (2007-06-01)

Ektacytometry Analysis of Post-splenectomy Red Blood Cell Properties Identifies Cell Membrane Stability Test as a Novel Biomarker of Membrane Health in Hereditary Spherocytosis
by: M. C. Berrevoets, et al.
Published: (2021-03-01)

Candidate genes that may be responsible for the unusual resistances exhibited by Bacillus pumilus SAFR-032 spores.
by: Madhan R Tirumalai, et al.
Published: (2013-01-01)